Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
M1 Molecule: A Promising Treatment for Optic Nerve Injury
Traumatic injury to the central nervous system (CNS), spinal cord, and optic nerve is the primary cause of disability and the second largest cause of mortality worldwide. CNS injuries frequently result in catastrophic loss of sensory, motor, and visual skills,…
Topcon and OphtAI Collaborate for AI Technology
Topcon Healthcare Solutions and OphtAI, a joint venture specialized in Artificial Intelligence (AI) for ophthalmology, have announced a partnership to integrate OphtAI into Topcon’s Harmony Referral System, and provide eye care professionals with smarter access to AI services. OphtAI’s state-of-the-art…
Fungal Endophthalmitis Outbreak in South Korea
South Korean ophthalmologists reported a fungal endophthalmitis outbreak after cataract surgery due to contaminated viscoelastic material. Researchers from the Department of Ophthalmology at Korea University Guro Hospital in Seoul, Korea, under the direction of Seong Woo Kim, MD, PhD, found…
Vision Correction Market Report | OBN
According to recent market research by Allied Market Research, the global vision correction market was worth $20,302.8 million in 2021, and is expected to grow at a compound annual growth rate (CAGR) of 7.4% from 2022 to 2031, reaching $41,252.7…
Frontera’s Trial for Retinitis Pigmentosa Kicks Off
Frontera Therapeutics has initiated a clinical trial for its gene therapy, FT-002, which is intended for the treatment of X-linked retinitis pigmentosa (XLRP). The first patient has already been given a dose of the gene therapy product. FT-002 is Frontera’s…
FDA Issues Warning Letter to RightEye
The FDA issued a Warning Letter1 on January 31, 2023, to RightEye, LLC, the manufacturer of the RightEye Vision System, for misbranding and adulteration. The RightEye Vision System is a Class II Nystagmograph medical device that has been cleared “recording,…
Regeneron’s EYLEA® Injection Approved for ROP
Regeneron Pharmaceuticals announced that the FDA granted its approval for the use of EYLEA® (aflibercept) Injection as a treatment option for preterm infants suffering from retinopathy of prematurity (ROP). This marks the first time that EYLEA has received approval for…
Endogena Receives FDA Fast Tract Designation for RP
Endogena Therapeutics announced that the US FDA has designated the investigation of its drug EA-2353 for the treatment of retinitis pigmentosa (RP) as a Fast Track development program. This process speeds up the availability of new drugs for serious conditions…
Smart Contact Lens That Diagnoses and Treats Glaucoma
A research team at POSTECH has recently developed a wireless theranostic smart contact lens that combines an IOP sensor and a flexible drug delivery system to control IOP measurement and drug administration in glaucoma. Glaucoma is a common eye disease…